Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Lee Seung-heon Signals Caution on Rate Hikes, Supports Higher Property Taxes to Cool Korea’s Housing Market 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Japanese beer and beverage maker Kirin is selling its China soft drinks joint venture to a Chinese investment fund, Plateau Consumer, for $994 million to enhance its pharmaceutical business.
The sale covers Kirin’s entire 40 percent stake in China Resources Kirin Beverages.
Established in 2011, China Resources Kirin Beverage had been expanding its business in China, making bottled water and bottled tea.
The move was part of its recent decision to review its investment portfolio, including foreign operations, under a management plan that runs through 2024. It comes shortly after Kirin decided to pull out of a joint venture brewery in Myanmar.
Kirin is focusing on certain areas, including pharmaceuticals and health science as well as food and beverages.
The Tokyo-based company has been streamlining its operations to focus on pharmaceutical projects like developing drugs for diseases that have no existing treatments and working on what it calls LC-Plasma to offer products that help maintain immune systems.
Kirin is among Japan’s top beer brands, and still has various global operations, including Four Roses Distillery in the U.S. and San Miguel Brewery in the Philippines.
.
